SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Kaare A) "

Sökning: WFRF:(Kaare A)

  • Resultat 31-31 av 31
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Zheng, Jie, et al. (författare)
  • Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.
  • 2023
  • Ingår i: Arthritis & rheumatology (Hoboken, N.J.). - 2326-5205. ; 75:10, s. 1781-1792
  • Tidskriftsartikel (refereegranskat)abstract
    • In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.A genome-wide association study meta-analysis was performed of circulating sclerostin levels in 33,961 European individuals. Mendelian randomization (MR) was used to predict the causal effects of sclerostin lowering on 15 atherosclerosis-related diseases and risk factors.We found that 18 conditionally independent variants were associated with circulating sclerostin. Of these, 1 cis signal in SOST and 3 trans signals in B4GALNT3, RIN3, and SERPINA1 regions showed directionally opposite signals for sclerostin levels and estimated bone mineral density. Variants with these 4 regions were selected as genetic instruments. MR using 5 correlated cis-SNPs suggested that lower sclerostin increased the risk of type 2 diabetes mellitus (DM) (odds ratio [OR] 1.32 [95% confidence interval (95% CI) 1.03-1.69]) and myocardial infarction (MI) (OR 1.35 [95% CI 1.01-1.79]); sclerostin lowering was also suggested to increase the extent of coronary artery calcification (CAC) (β=0.24 [95% CI 0.02-0.45]). MR using both cis and trans instruments suggested that lower sclerostin increased hypertension risk (OR 1.09 [95% CI 1.04-1.15]), but otherwise had attenuated effects.This study provides genetic evidence to suggest that lower levels of sclerostin may increase the risk of hypertension, type 2 DM, MI, and the extent of CAC. Taken together, these findings underscore the requirement for strategies to mitigate potential adverse effects of romosozumab treatment on atherosclerosis and its related risk factors.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 31-31 av 31
Typ av publikation
tidskriftsartikel (29)
annan publikation (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (28)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Christensen, Kaare (19)
Pedersen, Nancy L (9)
Gudnason, Vilmundur (9)
Ikram, M. Arfan (8)
Magnusson, Patrik K ... (7)
Peters, Annette (6)
visa fler...
Metspalu, Andres (6)
Elliott, Paul (6)
Salomaa, Veikko (5)
Cooper, Cyrus (5)
Ohlsson, Claes, 1965 (5)
Jonas, Jost B. (5)
Tynelius, Per (5)
Ridker, Paul M. (5)
Chasman, Daniel I. (5)
van Duijn, Cornelia ... (5)
Lehtimäki, Terho (5)
Rotter, Jerome I. (5)
Martin, Nicholas G. (5)
Kaprio, Jaakko (5)
Gatz, Margaret (5)
Rasmussen, Finn (5)
Sørensen, Thorkild I ... (5)
Harris, Tamara B (5)
Hofman, Albert (5)
Uitterlinden, André ... (5)
Psaty, Bruce M (5)
Franco, Oscar H. (5)
van der Harst, Pim (5)
Woo, Jean (5)
Reynolds, Chandra A. (5)
Franz, Carol E. (5)
Hardy, Rebecca (4)
Brenner, Hermann (4)
Staessen, Jan A (4)
Linneberg, Allan (4)
Amin, Najaf (4)
Mangino, Massimo (4)
Gieger, Christian (4)
Boomsma, Dorret I. (4)
Montgomery, Grant W. (4)
Rivadeneira, Fernand ... (4)
Loos, Ruth J F (4)
Hayward, Caroline (4)
Campbell, Archie (4)
Meisinger, Christa (4)
Liu, Jianjun (4)
Dahl Aslan, Anna K., ... (4)
Chen, Zhengming (4)
Saum, Kai-Uwe (4)
visa färre...
Lärosäte
Karolinska Institutet (15)
Göteborgs universitet (10)
Lunds universitet (9)
Uppsala universitet (8)
Umeå universitet (7)
Högskolan i Skövde (6)
visa fler...
Jönköping University (5)
Luleå tekniska universitet (2)
Örebro universitet (2)
Högskolan Dalarna (2)
Stockholms universitet (1)
Linköpings universitet (1)
Naturhistoriska riksmuseet (1)
visa färre...
Språk
Engelska (31)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (24)
Naturvetenskap (5)
Samhällsvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy